Replies to post #744365 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

What I expect to happen is a jump in share price followed by rampant short selling....to discourage longs into selling so they can cover on the cheap.

This action will most likely remain in effect until we hear of a significant deal (partnership or franchise). Only then will the chains be unleashed and we reach a MC of realistic value.

Assuming all that you say is true, NWBO management can foresee the risks that otherwise loyal longs would despair and sell and should vigorously and immediately help those who have been there for them.

They should not leave shareholders in the lurch for hours, days, weeks or months after MHRA approval news. They should not force them to have faith that NWBO is going to come through with follow-up news to check and reverse any slide in the SP.

Faith will be in short supply as many shareholders remember waiting in vain for the big journal article they were led to expect was going to coincide with TLD much as they are being led to expect partnership news

If this company really cares at all about retailers then their PR offensive must be strong and sustained and it must begin the moment MHRA news hits.

Anything less than that is a disservice to the retailers who have taken so many beating over the past decade but held their nose and bout all the dips (and the ditches and the canyons).

[dennisdave]

Hopefully this month.

Hopefully

[Investor082]

“What I expect to happen is a jump in share price followed by rampant short selling”.

— I agree with the above statement but not the reasons you gave for short selling. Short selling will happen because they know LP has nothing meaningful up her sleeve post approval except fluff PRs like Oncovir partnership, combo trial (but no cash to run and accelerate it), and so on, so it would be easy money for them again.

I do agree that the only news that will get shorts to move away from their games and give up will be a validation from big pharma including cash injection. Outside that, nothing else will matter and they will continue to question every move and short at every opportunity. It doesn’t help that this management team has a really bad history and have lost investors ton of money and opportunity cost over the last 10-15 years.